| Intrinsic Valuation of: AJANTPHARM | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2021 | - | - | EPS (FY) | 82 | Market Cap | ₹397B | |||||
| 2022 | - | - (-) | P/E Ratio | 39 | Total Asset | ₹62B | |||||
| 2023 | ₹6B | - (-) | Net Income | ₹11B | Total Debt | ₹0 | |||||
| 2024 | ₹6B | 2.4% (-8.7%) | EBITDA | ₹16B | Total Liab | ₹16B | |||||
| 2025 | ₹8B | 32.7% (18.8%) | Opr Margin | 51.44 | Debt/Equity | - | |||||
| 2026 | ₹2B | -80.5% (-83.3%) | PreTax Margin | 51.14 | BV/Share | 359 | |||||
| 5Y Average FCF | ₹6B | 3.5% (-24.4%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.00% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (3.5%) | ||||||||||
| 2027 | ₹3B | MBG Intrinsic Value | ₹736 | ||||||||
| 2028 | ₹3B | ||||||||||
| 2029 | ₹3B | ||||||||||
| 2030 | ₹3B | ||||||||||
| 2031 | ₹3B | ||||||||||
| 2032 | ₹3B | ||||||||||
| Terminal Value | ₹77B | Net Worth/Share | ₹362 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹66B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹1B | ₹538 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹0 | WACC | 6.5% | 506 | 549 | 604 | 674 | 767 | |||
| Equity Value | ₹67B | 7.1% | 451 | 484 | 524 | 574 | 638 | ||||
| Shares Outstanding | 124,935,624 | 7.8% | 406 | 432 | 462 | 499 | 545 | ||||
| 8.4% | 369 | 390 | 414 | 442 | 476 | ||||||
| DCF Intrinsic Value | ₹538 | 9.0% | 339 | 356 | 375 | 398 | 424 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||